Sanofi Multiple Sclerosis Drug Hit by Double Setback

Core Viewpoint - A U.S. regulatory decision regarding tolebrutinib will be delayed due to a late-stage trial for a different form of the disease not meeting its primary endpoint [1] Group 1 - The regulatory decision on tolebrutinib is postponed [1] - A late-stage trial for a different form of the disease did not achieve its main goal [1]